SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Colonna M) srt2:(2010-2014)"

Sökning: WFRF:(Colonna M) > (2010-2014)

  • Resultat 1-9 av 9
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • Tarrío, Diego, et al. (författare)
  • Measurement of the angular distribution of fission fragments using a PPAC assembly at CERN n_TOF
  • 2014
  • Ingår i: Nuclear Instruments and Methods in Physics Research Section A. - : Elsevier BV. - 0168-9002 .- 1872-9576. ; 743, s. 79-85
  • Tidskriftsartikel (refereegranskat)abstract
    • A fission reaction chamber based on Parallel Plate Avalanche Counters (PPACs) was built for measuring angular distributions of fragments emitted in neutron-induced fission of actinides at the neutron beam available at the Neutron Time-Of-Flight (n_TOF) facility at CERN. The detectors and the samples were tilted 45 degrees with respect to the neutron beam direction to cover all the possible values of the emission angle of the fission fragments. The main features of this setup are discussed and results on the fission fragment angular distribution are provided for the Th-232(n,f) reaction around the fission threshold. The results are compared with the available data in the literature, demonstrating the good capabilities of this setup.
  •  
3.
  • Tarrío, Diego, et al. (författare)
  • Fission Fragment Angular Distribution of Th-232(n,f) at the CERN n_TOF Facility
  • 2014
  • Ingår i: Nuclear Data Sheets. - Univ Santiago de Compostela, Santiago De Compostela, Spain. [Leong, L. S.; Audouin, L.; Tassan-Got, L.; Lederer, C.] IPN, CNRS, IN2P3, Orsay, France. [Altstadt, S.; Langer, C.; Lederer, C.; Reifarth, R.; Schmidt, S.; Weigand, M.] Goethe Univ Frankfurt, D-60054 Frankfurt, Germany. [Andrzejewski, J.; Marganiec, J.; Perkowski, J.] Univ Lodz, PL-90131 Lodz, Poland. [Barbagallo, M.; Colonna, N.; Mastromarco, M.; Meaze, M.; Tagliente, G.; Variale, V.] Ist Nazl Fis Nucl, I-70126 Bari, Italy. [Becares, V.; Cano-Ott, D.; Garcia, A. R.; Gonzalez-Romero, E.; Martinez, T.; Mendoza, E.] CIEMAT, E-28040 Madrid, Spain. [Becvar, F.; Krticka, M.; Kroll, J.; Valenta, S.] Charles Univ Prague, Prague, Czech Republic. [Belloni, F.; Berthoumieux, E.; Bosnar, D.; Chiaveri, E.; Fraval, K.; Gunsing, F.] CEA Saclay, Irfu, F-91191 Gif Sur Yvette, France. [Berthoumieux, E.; Boccone, V.; Bosnar, D.; Brugger, M.; Calviani, M.; Cerutti, F.; Chiaveri, E.; Chin, M.; Ferrari, A.; Guerrero, C.; Kadi, Y.; Losito, R.; Roman, F.; Rubbia, C.; Tsinganis, A.; Versaci, R.; Vlachoudis, V.] CERN, European Org Nucl Res, CH-1211 Geneva, Switzerland. [Billowes, J.; Ware, T.; Wright, T. J.] Univ Manchester, Manchester, Lancs, England. [Zugec, P.] Univ Zagreb, Fac Sci, Dept Phys, Zagreb 41000, Croatia. [Calvino, F.; Cortes, G.; Gomez-Hornillos, M. B.; Riego, A.] Univ Politecn Cataluna, Barcelona, Spain. [Carrapico, C.; Goncalves, I. F.; Sarmento, R.; Vaz, P.] Univ Tecn Lisboa, Inst Super Tecn, Inst Tecnol Nucl, P-1096 Lisbon, Portugal. [Cortes-Giraldo, M. A.; Praena, J.; Quesada, J. M.] Univ Seville, Seville, Spain. [Diakaki, M.; Karadimos, D.; Kokkoris, M.; Vlastou, R.] Natl Tech Univ Athens, GR-10682 Athens, Greece. [Domingo-Pardo, C.; Giubrone, G.; Tain, J. L.] Univ Valencia, CSIC, Inst Fis Corpuscular, E-46003 Valencia, Spain. [Dzysiuk, N.; Mastinu, P. F.] Ist Nazl Fis Nucl, Lab Nazl Legnaro, Milan, Italy. [Eleftheriadis, C.; Manousos, A.] Aristotle Univ Thessaloniki, GR-54006 Thessaloniki, Greece. [Ganesan, S.; Gurusamy, P.] Bhabha Atom Res Ctr, Bombay 400085, Maharashtra, India. [Griesmayer, E.; Jericha, E.; Leeb, H.; Weiss, C.] Vienna Univ Technol, Inst Atom, Vienna, Austria. [Jenkins, D. G.; Vermeulen, M. J.] Univ York, York YO10 5DD, N Yorkshire, England. [Kaeppeler, F.] Karlsruhe Inst Technol, Inst Kernphys, D-76021 Karlsruhe, Germany. [Koehler, P.] Oak Ridge Natl Lab, Oak Ridge, TN 37831 USA. [Lederer, C.; Pavlik, A.; Wallner, A.] Univ Vienna, Fac Phys, A-1010 Vienna, Austria. [Massimi, C.; Mingrone, F.; Vannini, G.] Univ Bologna, Dipartimento Fis, I-40126 Bologna, Italy. [Massimi, C.; Mingrone, F.; Vannini, G.] Sez INFN Bologna, Bologna, Italy. [Mengoni, A.; Ventura, A.] Agenzia Nazl Nuove Tecnol, Eenergia & Sviluppo Econ Sostenibile ENEA, Bologna, Italy. [Milazzo, P. M.] Ist Nazl Fis Nucl, Trieste, Italy. [Mirea, M.; Roman, F.] Horia Hulubei Natl Inst Phys & Nucl Engn, IFIN HH, Bucharest, Romania. [Mondalaers, W.; Plompen, A.; Schillebeeckx, P.] European Commiss JRC, Inst Reference Mat & Measurements, B-2440 Geel, Belgium. [Rauscher, T.] Univ Basel, Dept Phys & Astron, Basel, Switzerland. [Rubbia, C.] Ist Nazl Fis Nucl, Lab Nazl Gran Sasso, Assergi, AQ, Italy. : Elsevier BV. - 0090-3752 .- 1095-9904. ; 119, s. 35-37
  • Tidskriftsartikel (refereegranskat)abstract
    • The angular distribution of fragments emitted in neutron-induced fission of Th-232 was measured in the white spectrum neutron beam at the n_TOF facility at CERN. A reaction chamber based on Parallel Plate Avalanche Counters (PPAC) was used, where the detectors and the targets have been tilted 45 degrees with respect to the neutron beam direction in order to cover the full angular range of the fission fragments. A GEANT4 simulation has been developed to study the setup efficiency. The data analysis and the preliminary results obtained for the Th-232(n,f) between fission threshold and 100 MeV are presented here.
  •  
4.
  • Hannan, T. J., et al. (författare)
  • Inhibition of cyclooxygenase-2 prevents chronic and recurrent cystitis
  • 2014
  • Ingår i: EBioMedicine. - : Elsevier. - 2352-3964. ; 1:1, s. 46-57
  • Tidskriftsartikel (refereegranskat)abstract
    • The spread of multidrug-resistant microorganisms globally has created an urgent need for novel therapeuticstrategies to combat urinary tract infections (UTIs). Immunomodulatory therapy may provide benefit, as treatmentof mice with dexamethasone during acute UTI improved outcome by reducing the development of chroniccystitis, which predisposes to recurrent infection. Herewe discovered soluble biomarkers engaged inmyeloid celldevelopment and chemotaxis that were predictive of future UTI recurrence when elevated in the sera of youngwomen with UTI. Translation of these findings revealed that temperance of the neutrophil response early duringUTI, and specifically disruption of bladder epithelial transmigration of neutrophils by inhibition ofcyclooxygenase-2, protected mice against chronic and recurrent cystitis. Further, proteomics identified bladderepithelial remodeling consequent to chronic infection that enhances sensitivity to neutrophil damage. Thus, cyclooxygenase-2 expression during acute UTI is a critical molecular trigger determining disease outcome anddrugs targeting cyclooxygenase-2 could prevent recurrent UTI.
  •  
5.
  • Kleinberger, G., et al. (författare)
  • TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
  • 2014
  • Ingår i: Science Translational Medicine. - : American Association for the Advancement of Science (AAAS). - 1946-6234 .- 1946-6242. ; 6:243
  • Tidskriftsartikel (refereegranskat)abstract
    • Genetic variants in the triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to Nasu-Hakola disease, Alzheimer's disease (AD), Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia (FTD), and FTD-like syndrome without bone involvement. TREM2 is an innate immune receptor preferentially expressed by microglia and is involved in inflammation and phagocytosis. Whether and how TREM2 missense mutations affect TREM2 function is unclear. We report that missense mutations associated with FTD and FTD-like syndrome reduce TREM2 maturation, abolish shedding by ADAM proteases, and impair the phagocytic activity of TREM2-expressing cells. As a consequence of reduced shedding, TREM2 is virtually absent in the cerebrospinal fluid (CSF) and plasma of a patient with FTD-like syndrome. A decrease in soluble TREM2 was also observed in the CSF of patients with AD and FTD, further suggesting that reduced TREM2 function may contribute to increased risk for two neurodegenerative disorders.
  •  
6.
  •  
7.
  • Allemani, Claudia, et al. (författare)
  • Breast cancer survival in the US and Europe: a CONCORD high-resolution study
  • 2013
  • Ingår i: International Journal of Cancer. - : Wiley. - 0020-7136. ; 132:5, s. 1170-1181
  • Tidskriftsartikel (refereegranskat)abstract
    • Breast cancer survival is reportedly higher in the US than in Europe. The first worldwide study (CONCORD) found wide international differences in age-standardized survival. The aim of this study is to explain these survival differences. Population-based data on stage at diagnosis, diagnostic procedures, treatment and follow-up were collected for about 20,000 women diagnosed with breast cancer aged 15-99 years during 1996-98 in 7 US states and 12 European countries. Age-standardized net survival and the excess hazard of death up to 5 years after diagnosis were estimated by jurisdiction (registry, country, European region), age and stage with flexible parametric models. Breast cancers were generally less advanced in the US than in Europe. Stage also varied less between US states than between European jurisdictions. Early, node-negative tumors were more frequent in the US (39%) than in Europe (32%), while locally advanced tumors were twice as frequent in Europe (8%), and metastatic tumors of similar frequency (5-6%). Net survival in Northern, Western and Southern Europe (81-84%) was similar to that in the US (84%), but lower in Eastern Europe (69%). For the first 3 years after diagnosis the mean excess hazard was higher in Eastern Europe than elsewhere: the difference was most marked for women aged 70-99 years, and mainly confined to women with locally advanced or metastatic tumors. Differences in breast cancer survival between Europe and the US in the late 1990s were mainly explained by lower survival in Eastern Europe, where low healthcare expenditure may have constrained the quality of treatment.
  •  
8.
  •  
9.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-9 av 9

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy